In studies, the most serious side effects of the combination<unk> /doxorubicin were neutropenia (low count of neutrophil white blood cells) with a severity of grade 3 or 4 in 55% of patients, and musculoskeletal pain grade 3 or 4 in 8% of patients. Common milder side effects were lymphopenia, headache, diarrhoea, nausea and vomiting, mucositis, and reactions at the infusion site; all typical effects of cancer therapies.
Olaratumab
Ustekinumab
Emapalumab
Evolocumab
Evinacumab
Dupilumab
Anifrolumab
Alirocumab